[1]
Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584.
[2]
Bharti, S.K.; Singh, S.K. Recent developments in the field of anticancer metallopharmaceuticals. Int. J. Pharm. Tech. Res., 2009, 1(4), 1406-1420.
[3]
Momekov, G.; Bakalova, A.; Karaivanova, M. Novel approaches towards development of non-classical platinum-based antineoplastic agents: Design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity. Curr. Med. Chem., 2005, 12(19), 2177-2191.
[4]
Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat., 2005, 8(3), 131-146.
[5]
Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev., 2007, 33(1), 9-23.
[6]
Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int., 2008, 73(9), 994-1007.
[7]
Abu-Surrah, A.S.; Kettunen, M. Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin. Curr. Med. Chem., 2006, 13(11), 1337-1357.
[8]
Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15), 1869-1883.
[9]
Wang, X.; Guo, Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer. Agents Med. Chem., 2007, 7, 19-34.
[10]
Pasini, A.; Perego, P.; Balconi, M.; Lupatini, M. Cisplatin analogues with sulfur donor ligands. (Ethylenediamine)Platinum(II) complexes with ligands possessing a sulfinyl or sulfanyl group linked to an anionic oxygen donor atom. Reactivity and cytotoxicity. J. Chem. Soc., Dalton Trans., 1995, 80(4), 579-585.
[11]
Chui, W.; Wong, T.; Thenomozhiyal, J. Anticonvulsant activity of phenylmethylene-hydantoins: A structure-activity relation study. J. Med. Chem., 2004, 47, 1527-1535.
[12]
Spengler, G.; Evaristo, M.; Handzlik, J.; Serly, J.; Molnár, J.; Viveiros, M.; Kieć-Kononowicz, K.; Amaral, L. Biological activity of hydantoin derivatives on P-Glycoprotein (ABCB1) of mouse lymphoma cells. Anticancer Res., 2010, 30(12), 4867-4872.
[13]
McKeage, M.J.; Higgins, J.D.; Kelland, L.R. Platinum and other metal coordination compounds in cancer chemotherapy. Br. J. Cancer, 1991, 64(4), 788-792.
[14]
Fern, J.; Gil, P.; Iturrino, L.; Matesanz, E.; Meert, T.F.; Megens, A.; Sipido, V.K. Synthesis and structure - activity relationship of 2-(Aminoalkyl)-3,3a,8,12b-tetrahydro-2H- dibenzocyclohepta[1,2-b]furan derivatives: A novel series of 5-HT(2A/2C) receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14(11), 2765-2771.
[15]
Bakalova, A.; Nikolova-Mladenova, B.; Buyukliev, R.; Cherneva, E.; Momekov, G.; Ivanov, D. Synthesis, DFT calculations and characterisation of new mixed Pt(II) complexes with 3-thiolanespiro-5′-hydantoin and 4-thio-1H-tetrahydropyranspiro-5′-hydantoin. Chem. Pap., 2016, 70(1), 93-100.
[16]
Bakalova, A.; Buyukliev, R.; Momekov, G. Synthesis, DFT calculations and cytotoxic investigation of platinum complexes with 3-thiolanespiro-5′-hydantoin and 4-thio-1H-tetrahydropyranespiro-5′-hydantoin. J. Mol. Struct., 2015, 1091, 118-124.
[17]
Bierbach, U.; Qu, Y.; Hambley, T.W.; Peroutka, J.; Nguyen, H.L.; Doedee, M.; Farrell, N. Synthesis, structure, biological activity, and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3) L] (L = planar nitrogen base). Effect of L and Cis/Trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg. Chem., 1999, 38(15), 3535-3542.
[18]
Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A: Found. Crystallogr, 2008, A64, 112-122.
[19]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[20]
Konstantinov, S.M.; Elbl, H.; Berger, M.R. BCR-ABL Influences the antileukaemic efficacy of alkylphosphocholines. Br. J. Haematol., 1999, 107(2), 365-374.
[21]
Nakamoto, K. Infrared and Raman Spectra of Inorganic and Coordination Compounds; 6th ed.; A John Wiley & Sons: New Jersey. , 2009.
[22]
Michalska, D.; Wysokiński, R. Molecular structure and bonding in platinum-picoline anticancer complex: Density functional study. Collect. Czech. Chem. Commun., 2003, 69, 63-72.
[23]
Křikavová, R.; Vančo, J.; Šilha, T.; Marek, J.; Trávníček, Z. Synthesis, characterization, DNA binding studies and in vitro cytotoxicity of platinum(II)-dihalogenido complexes containing bidentate chelating N-donor ligands. J. Coord. Chem., 2016, 69, 2422-2436.
[24]
Amharar, Y.; Petit, S.; Sanselme, M.; Cartigny, Y.; Petit, M.; Coquerel, G. Crystal structures, dehydration mechanism, and chiral discrimination in the solid state of a hydantoin derivative. Cryst. Growth Des., 2011, 11, 2453-2462.
[25]
Coquerel, G.; Petit, M.N.; Robert, F. Structure of (+)- (S)-5-phenyl-5-ethylhydantoin. Acta Crystallogr. Sect C, 1993, 49(4), 824-825.
[26]
Kashif, M.K.; Hussain, A.; Rauf, M.K.; Ebihara, M.; Hameed, S. 5-(4-Fluorophenyl)-5-methylimidazolidine-2,4-Dione. Acta Crystallogr. Sect. E Struct. Rep. Online, 2008, E64, o444.
[27]
Martin, T.; Massif, C.; Wermester, N.; Linol, J.; Tisse, S.; Cardinael, P.; Coquerel, G.; Bouillon, J.P. Efficient preparation of enantiomerically pure α-aryl-α- trifluoromethylglycines via auto seeded programmed polythermic preferential crystallization of 5-aryl-5-trifluoromethylhydantoins. Tetrahedron Asymmetry, 2011, 22(1), 12-21.
[28]
Sabounchei, S.J.; Shahriary, P.; Gholiee, Y.; Salehzadeh, S.; Khavasi, H.R.; Chehregani, A. Platinum and palladium complexes with
5-methyl-5-(2-pyridyl)-2,4-imidazolidenedione: Synthesis, crystal
and molecular structure, theoretical study, and pharmacological investigation. Inorg. Chim. Acta, 2014, 409(PB), 265-275.
[29]
Todorov, P.T.; Petrova, R.N.; Naydenova, E.D.; Shivachev, B.L. Structure, conformation and hydrogen bonding of two amino-cycloalkanespiro-5-hydantoins. Cent. Eur. J. Chem., 2009, 7(1), 14-19.
[30]
Cruz-Cabeza, A.J.; Schwalbe, C.H. Observed and predicted hydrogen bond motifs in crystal structures of hydantoins, Dihydrouracils and uracils. New J. Chem., 2012, 36(6), 1347.
[31]
Sundquist, W.I.; Ahmed, K.J.; Hollis, L.S.; Lippard, S.J. Solvolysis reactions of cis- and trans-diamminedichloroplatinum(II) in dimethyl sulfoxide. Structural characterization and DNA binding of trans-bis(ammine)chloro(DMSO) platinum(1+). Inorg. Chem., 1987, 26(10), 1524-1528.
[32]
Trainer, D.L.; Kline, T.; McCabe, F.L.; Faucette, L.F.; Field, J.; Chaikin, M.; Anzano, M.; Rieman, D.; Hoffstein, S.; Li, D.J. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer, 1988, 41(2), 287-296.
[33]
Baik, M.H.; Friesner, R.A.; Lippard, S.J. Theoretical study of cisplatin binding to purine bases: Why does cisplatin prefer guanine over adenine? J. Am. Chem. Soc., 2003, 125(46), 14082-14092.
[34]
Reedijk, J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev., 1999, 99(9), 2499-2510.
[35]
Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A: Found. Crystallogr, 2008, A64, 112-122.